XML 40 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Segment Reporting SEGMENT REPORTING
Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. Our reportable segments include diagnostic and information technology-based products and services for the veterinary market, which we refer to as the Companion Animal Group (“CAG”), water quality products (“Water”) and diagnostic products and services for livestock and poultry health and to ensure the quality and safety of milk and improve producer efficiency, which we refer to as Livestock, Poultry and Dairy (“LPD”). Although our LPD segment does not meet the quantitative thresholds to be reported as a separate segment, we believe it is important to disaggregate these revenues as a major product and service category within our Other reportable segment given its distinct markets, and therefore we have elected to report LPD as a reportable segment. Our Other operating segment combines and presents products and services for the human medical diagnostics (“OPTI Medical”) market with our out-licensing arrangements. Assets are not allocated to segments for internal reporting purposes.

The following is a summary of segment performance:
(in thousands)For the Three Months Ended September 30,
CAGWaterLPDOtherConsolidated Total
2021
Revenue$732,495 $38,143 $29,126 $10,657 $810,421 
Income from operations$201,947 $17,599 $3,600 $2,816 $225,962 
Interest expense, net(7,012)
Income before provision for income taxes218,950 
Provision for income taxes43,772 
Net income175,178 
Less: Net loss attributable to noncontrolling interest(57)
Net income attributable to IDEXX Laboratories, Inc. stockholders$175,235 
2020
Revenue$638,017 $33,272 $36,971 $13,529 $721,789 
Income from operations$139,434 $15,243 $10,505 $6,674 $171,856 
Interest expense, net(7,902)
Income before provision for income taxes163,954 
Provision for income taxes17,633 
Net income146,321 
Less: Net income attributable to noncontrolling interest102 
Net income attributable to IDEXX Laboratories, Inc. stockholders$146,219 
(in thousands)For the Nine Months Ended September 30,
CAGWaterLPDOtherConsolidated Total
2021     
Revenue$2,170,857 $109,374 $101,920 $32,119 $2,414,270 
Income from operations$649,892 $49,599 $24,276 $9,070 $732,837 
Interest expense, net(22,066)
Income before provision for income taxes710,771 
Provision for income taxes128,698 
Net income582,073 
Less: Net loss attributable to noncontrolling interest(1)
Net income attributable to IDEXX Laboratories, Inc. stockholders$582,074 
2020
Revenue$1,756,113 $95,537 $103,369 $30,698 $1,985,717 
Income from operations$426,062 $43,383 $28,417 $11,567 $509,429 
Interest expense, net(24,880)
Income before provision for income taxes484,549 
Provision for income taxes77,376 
Net income407,173 
Less: Net income attributable to noncontrolling interest187 
Net income attributable to IDEXX Laboratories, Inc. stockholders$406,986 
See “Note 3. Revenue Recognition” for a summary of disaggregated revenue by reportable segment and by major product and service category for the three and nine months ended September 30, 2021 and 2020.